- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.02. | BD announces intent to sell Life Sciences business, beats Street in Q1 | ||
| 05.02. | FDA warns of potential missed alerts with smartphone-connected diabetes devices | ||
| 05.02. | CVRx stock dips on Q4 EPS miss | ||
| 05.02. | Newronika wins FDA IDE for adaptive deep brain stim tech | ||
| 05.02. | Wandercraft launches clinical trial of personal exoskeleton | ||
| 05.02. | CereVasc study data backs eShunt system | ||
| 05.02. | Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4 | ||
| 04.02. | Abbott launches initiative to combat diabetes stigma | ||
| 04.02. | FDA clears AI 3D head, neck imaging tech from RapidAI | ||
| 04.02. | Movano Health kicks off cuffless blood pressure device study | ||
| 04.02. | Pulse Biosciences has a new CFO | ||
| 04.02. | Glucotrack completes first-in-human continuous blood glucose monitor implant study | ||
| 03.02. | Fractyl Health announces layoffs as it pivots to gene therapy | ||
| 03.02. | Surmodics reports first clinical use of thrombectomy system | ||
| 03.02. | Activist investors reportedly push BD to sell Life Sciences biz | ||
| 03.02. | GE HealthCare invests $138M in Ireland contrast media manufacturing plant | ||
| 03.02. | Baxter CEO Almeida to retire, Kidney Care business becomes standalone company | ||
| 31.01. | Butterfly Network raising $76.5 million from public offering | ||
| 31.01. | Beta Bionics goes public with upsized $204M IPO | ||
| 31.01. | ResMed revenue up 10% in Q2 - but GLP-1 questions remain | ||
| 30.01. | Rad AI raises $60M in Series C to bring generative AI to radiology | ||
| 30.01. | Getinge to phase out its surgical perfusion business | ||
| 30.01. | Stereotaxis has first order for its next-gen surgical robot | ||
| 29.01. | Enovis continues facility expansion in central Texas | ||
| 29.01. | Intuitive fends off antitrust lawsuit from Surgical Instrument Service |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
